Biomerica and Leading UAE Healthcare Company Forge a Path to Enhanced Colorectal and Breast Screening with Exclusive Multi-Year Distribution Agreement

• Dubai Healthcare Authority Granted Insurance Reimbursement for Biomerica’s EZ Detect Colon Disease Screening Test

• EZ Detect is a simple FDA cleared 2-minute at-home test that detects early warning signs of colorectal cancer, the third most common cancer worldwide
  
• Aware is an FDA cleared simple at-home device clinically tested to increase sensitivity in breast self-exams; about 80% of breast cancers are detected by women themselves noticing changes in their breasts
  
• First order placed for both Colon Disease and Breast screening products
  

IRVINE, Calif., April 29, 2024 (GLOBE NEWSWIRE) -- Biomerica Inc. (Nasdaq: BMRA), is proud to announce a multi-year exclusive distribution agreement with one of the UAE's most substantial healthcare conglomerates. This strategic alliance is set to revolutionize the accessibility and efficiency of colorectal cancer screening and breast examination technologies in the region.

Strategic Partnership Highlights
Biomerica has entered into a multi-year agreement with a UAE-based multi-billion dollar healthcare powerhouse, commencing with a large initial order for the Company’s at-home screening products, EZ Detect and Aware. The partnership will not only enhance the distribution of these innovative health screening tools across the UAE, but also work to engage various governmental health departments in integrating these tests into national health protocols.

The collaboration between Biomerica and its UAE partner reflects a shared vision of reducing the burden of cancer through early detection and innovative healthcare solutions. The companies are also exploring opportunities to introduce additional Biomerica products to the UAE, expanding their impact on healthcare improvement.

EZ Detect: Colorectal Screening Made Easy
EZ Detect stands out as the most user-friendly at-home screening test for colorectal diseases currently available on the market. It detects occult (hidden) blood in stool, which can be an early sign of colorectal cancer. FDA cleared and meticulously designed for convenience, EZ Detect eliminates the need for cumbersome stool handling, offering a discreet and rapid screening experience directly in the comfort of the patient's home. With a straightforward process—simply drop the test pad into the toilet, observe for a color change on the pad, then flush—the barrier to regular screening is significantly lowered, driving increased adoption rates and facilitating early detection efforts. This simplicity is critical in increasing screening adoption and early cancer detection rates. The recent approval of insurance reimbursement for EZ Detect by the Dubai Health Authority further underscores its public health importance and boosts its affordability and accessibility.